Adjusted EBITDA of $996 M for the fourth quarter, $3,684 Mfor the full year;R&D Solutions quarterly bookings of over $2.5 billion, representing a book-to-bill ratio of 1.20x ;R&D Solutions contracted ...
Q4 2024 Management View CEO Eric Ashleman highlighted strong performance in Q4 2024, with notable achievements in the Health & Science Technologies (HST) segment, including impactful projects in ...
Results that may be inaccessible to you are currently showing.